Table 2 Transplantation details of patients with hepatitis‑associated aplastic anaemia (HAAA).

Interval from diagnosis to HSCT, days, median (range)

75 (34–412)

IST before HSCT

 ATG-based

2 (5.7%)

 CsA-based

22 (62.9%)

 No

11 (31.4%)

HCT-CI pre-HSCT

 0–1

32 (100.0%)^a

 ≥ 2

0 (0.0%)^a

Graft type

 PB only

29 (82.9%)

 PB + BM

5 (14.3%)

 BM only

1 (2.9%)

Blood type

 Match

24 (68.6%)

 Major mismatch

2 (5.7%)

 Minor mismatch

5 (14.3%)

 Mismatch

4 (11.4%)

Donor–patient sex match

 Female to female

6 (17.1%)

 Female to male

7 (20.0%)

 Male to male

16 (45.7%)

 Male to female

6 (17.1%)

HLA type

 5/10

10 (31.3%)^a

 6/10

1 (3.1%)^a

 7/10

3 (9.4%)^a

 8/10

2 (6.3%)^a

 9/10

0 (0.0%)^a

 10/10

16 (50.0%)^a

Conditioning regimen

 Bu + Cy + Flu + ATG

6 (17.1%)

 Cy + Flu + ATG

29 (82.9%)

GVHD prophylaxis

 CsA + MTX + MMF

12 (37.5%)

 FK506 + MTX + MMF

2 (6.3%)

 CsA + MTX

15 (46.9%)

 FK506 + MTX

3 (9.4%)

Cell compositions in allografts

 MNC, 10⁸/kg

10.00 (8.02–11.90)

 CD34+ cells, 10⁶/kg

2.92 (2.29–4.16)

 CD3+ T cells, 10⁶/kg

169.17 (109.67–230.26)

 CD3+ CD4+ T cells, 10⁶/kg

86.57 (56.60–123.30)

 CD3+ CD8+ T cells, 10⁶/kg

64.94 (41.39–105.77)

 CD19+ B cells, 10⁶/kg

38.52 (17.08–66.63)